Yu-Hsin Lin | executive |
Nathan L. Mata | executive |
Hao-Yuan Chuang | executive |
Yi Chen | analyst |
Basma Radwan Ibrahim | analyst |
Hello, and thank you for joining us to discuss Belite Bio's First Quarter 2024 Financial Results.
Joining the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Nathan Mata, Chief Scientific Officer; and Hao-Yuan Chuang, Chief Financial Officer.
Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs.